Answers are grounded in this paper and cite their sources.
Case report shows successful resolution of grade 4 hypertriglyceridemia with dual lipid-lowering therapy in lung adenocarcinoma, highlighting a viable management strategy.
Hyperlipidemia are the most common treatment-related adverse effects of lorlatinib, severe hyperlipidemia can lead to discontinuation of medication, thrombosis, and even life-threatening conditions. Lorlatinib most often reported to causing grade 1-2 hyperlipidemia, and currently there is no treatment method for grade 4 hypertriglyceridemia. Herein, we report a case of a 47-year-old female with multiple brain metastases from lung adenocarcinoma, developed to grade 4 hypertriglyceridemia within 9 months of administration of lorlatinib and was managed successfully with dual lipid-lowering therapy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: